Investigating methotrexate dosing and effects for Burkitt lymphoma in Malawi
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
This study is looking to make treatments better for kids and young adults with Burkitt lymphoma by testing the safest dose of a chemotherapy drug called methotrexate and finding out how it works in the body, all while keeping an eye on how patients feel during treatment.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10924460 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for Burkitt lymphoma, a common cancer in children and young adults in Sub-Saharan Africa. The project will involve a pilot clinical trial to find the highest safe dose of methotrexate, a key chemotherapy drug. Additionally, it will develop a model to understand how the drug behaves in the body and create a tool to assess side effects from the patient's perspective. The goal is to enhance future clinical trials and treatment protocols for this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with Burkitt lymphoma in Sub-Saharan Africa.
Not a fit: Patients with other types of cancers or those outside the age range of 0-21 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Burkitt lymphoma.
How similar studies have performed: Similar research has shown promise in optimizing cancer treatments in resource-limited settings, indicating potential for success in this approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Westmoreland, Katherine Douglas — Univ of North Carolina Chapel Hill
- Study coordinator: Westmoreland, Katherine Douglas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.